Cargando…

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer

BACKGROUND: Recent phase III randomized trials have suggested that neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) is a treatment option for patients with advanced epithelial ovarian cancer. This study aimed to use CA-125 and computed tomography (CT) scanning to generate a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Kazuto, Kitahara, Yoshikazu, Nishimura, Toshio, Yamashita, Soichi, Kigure, Keiko, Ito, Ikuro, Kanuma, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427056/ https://www.ncbi.nlm.nih.gov/pubmed/32791996 http://dx.doi.org/10.1186/s12957-020-01978-6

Ejemplares similares

Reassessment of intensive surveillance practices adopted for endometrial cancer survivors
por: Nakamura, Kazuto, et al.
Publicado: (2022)

Utility of vaginal vault cytology in the local recurrence of cervical cancer
por: Nakamura, Kazuto, et al.
Publicado: (2023)

The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery
por: Zeng, Jing, et al.
Publicado: (2017)

Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor
por: Nishimura, Toshio, et al.
Publicado: (2015)

CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
por: Furukawa, Naoto, et al.
Publicado: (2013)

An electrical scalpel conization versus Shimodaira-Taniguchi conization procedure for cervical intraepithelial neoplasia
por: Kigure, Keiko, et al.
Publicado: (2018)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease
por: Liang, Wei-feng, et al.
Publicado: (2021)

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
por: Yoneoka, Yutaka, et al.
Publicado: (2019)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
por: He, Minjun, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
por: Menczer, Joseph, et al.
Publicado: (2011)

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer
por: Kang, Sokbom, et al.
Publicado: (2011)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
por: Iura, Ayaka, et al.
Publicado: (2018)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients
por: Iwase, Haruko, et al.
Publicado: (2015)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
por: Vandenput, I, et al.
Publicado: (2009)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap
por: Franca, Carlos Antônio da Silva, et al.
Publicado: (2014)

The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
por: Qin, Meng, et al.
Publicado: (2017)

Predictors of residual disease after debulking surgery in advanced stage ovarian cancer
por: Abbas-Aghababazadeh, Farnoosh, et al.
Publicado: (2023)

The leucocyte nadir, a predictor of chemotherapy efficacy?
por: Kvinnsland, S
Publicado: (1999)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Safety and feasibility of robotic surgery in selected ovarian cancer patients undergoing interval debulking surgery
por: Iavazzo, Christos, et al.
Publicado: (2020)

Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma
por: Chambers, Laura M., et al.
Publicado: (2021)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer
por: Chudecka-Głaz, Anita Monika, et al.
Publicado: (2014)

Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer
por: Nishimura, Shuichi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_25mra4o8t0evgo9qkmbd1tq0pp